Dr Lalchandani Labs Ltd H1 FY26 Half-Yearly Results: ₹2.05 Cr Revenue, ₹0.20 Cr PAT, Promoters Exit Faster Than Patients
1. At a Glance – The Lab Coat Looks Clean, The Balance Sheet… Not So Much
Dr Lalchandani Labs Ltd is one of those microcap healthcare stocks that looks harmless at first glance—white lab coat, NABL accreditation, diagnostic tests, Delhi NCR presence—and then you open the financials and suddenly the ECG monitor starts beeping. With a market cap of about ₹9.49 crore and a current price hovering near ₹21.9, this is a company that lives in the deep SME alley of Indian diagnostics, far away from the air-conditioned lounges of Dr Lal PathLabs and Metropolis.
Latest half-year numbers show sales of ₹2.05 crore and PAT of ₹0.20 crore, which on paper looks like a decent recovery compared to last year’s chaos. Profit grew sequentially even though revenue dipped slightly QoQ. Stock P/E sits around 20, price-to-book is 0.93, and ROE is a modest 3%—basically, valuation says “cheap”, returns say “don’t get excited”, and promoters say “we are slowly leaving the party”.
The stock has delivered about 23% return over one year, which sounds impressive until you realize three-year returns are negative and promoter holding has collapsed from 60% to 31%. The business is alive, the lab machines are running, but ownership confidence is clearly on life support. Curious already? Good. Let’s scrub in.
2. Introduction – A Diagnostic Lab That Diagnoses Everyone Except Itself
Dr Lalchandani Labs was incorporated in 2011 and operates diagnostic laboratories and collection centres across Delhi/NCR. On paper, it ticks many credibility boxes: NABL accreditation, empanelment with CGHS, DMC, DDA, Airports Authority of India, and Delhi Government schemes. This is not some shady galli lab testing blood samples next to a paan shop. Institutionally, it looks legit.
But markets don’t pay for legitimacy alone; they pay for scale, consistency, governance, and capital discipline. And this is where the story becomes… interesting. The company had its golden years pre-COVID, then stumbled badly post-COVID with losses, negative ROE, ballooning working capital days, and audit qualifications that would give a CFO nightmares.
FY25 and H1 FY26 show signs of recovery—profits are back, interest cost is under control, and operating margins look respectable. But recovery stories are only fun when promoters stick around to enjoy them. Here, promoters are reducing stake aggressively while the company simultaneously announces rights issues worth ₹4.33 crore. That contradiction alone deserves a full forensic episode.
So the big question: is this a genuine turnaround lab quietly stabilizing, or a financial report that looks healthy under a microscope but falls apart under an MRI? Let’s investigate.
3. Business Model – WTF Do They Even Do With All These Test Tubes?
At its core, Dr Lalchandani Labs is a diagnostic services provider. The company operates 5 self-sufficient laboratories and 15 collection centres across Delhi/NCR. Samples come in, tests go out, reports get delivered—classic pathology economics.
The service bouquet is actually quite wide for a company this small:
Pathology services include biochemistry, hematology, histopathology, microbiology, immunoassays, molecular pathology, DNA and genetic testing. Radiology services cover X-ray, ultrasound, Doppler, ECG, TMT, and 2D echo. There’s also hospital lab management, blood bank services, corporate health checkups, and home sample collection.
Revenue mix historically was B2C ~53% and B2B ~47%, which means half the business depends on institutional clients like government bodies. This is both a blessing and a curse. Blessing because volumes are stable. Curse because payments arrive slower than government file movement—reflected clearly in 431 debtor days.
The model is asset-heavy relative to scale. Machines depreciate, staff costs are fixed, and pricing power is limited. Unlike big chains, this lab can’t squeeze suppliers or upsell wellness packages aggressively. It survives on credibility, empanelments, and local relationships.
So yes, the business is real. Profitable at maturity. But brutally unforgiving if working capital slips. And oh boy, working capital has slipped badly here.
4. Financials Overview – Half-Yearly Results Under the Microscope
Result Type Locked: Half-Yearly Results (H1 FY26) Annualised EPS = Latest EPS × 2
Half-Yearly Comparison Table (₹ in Crores)
Source table
Metric
Latest H1 FY26
H1 FY25
H2 FY25
YoY %
QoQ %
Revenue
2.05
2.13
2.33
-3.8%
-12.0%
EBITDA
0.26
0.54
0.51
-51.9%
-49.0%
PAT
0.20
0.15
0.27
+33.3%
-25.9%
EPS (₹)
0.46
0.35
0.62
+31.4%
-25.8%
Annualised EPS = ₹0.92
Now here’s the comedy: revenue is down, EBITDA is down sharply, but PAT is up YoY. How? Lower interest cost and tax gymnastics. This is not operational brilliance;
